相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa)
Lionel Couzi et al.
BLOOD (2012)
Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients
Maria Angeles Clari et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Factors Contributing to Variability of Quantitative Viral PCR Results in Proficiency Testing Samples: a Multivariate Analysis
R. T. Hayden et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis
Guy Boivin et al.
JOURNAL OF CLINICAL VIROLOGY (2012)
Homozygosity for the Toll-Like Receptor 2 R753Q Single-Nucleotide Polymorphism Is a Risk Factor for Cytomegalovirus Disease After Liver Transplantation
Seung H. Kang et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial
Mohamed A. Kharfan-Dabaja et al.
LANCET INFECTIOUS DISEASES (2012)
Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia
Luiz F. Lisboa et al.
TRANSPLANTATION (2012)
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial
Oliver Witzke et al.
TRANSPLANTATION (2012)
Cytomegalovirus Disease in Kidney Transplant Recipients: Incidence, Clinical Profile, and Risk Factors
E. Cordero et al.
TRANSPLANTATION PROCEEDINGS (2012)
Post-Renal Transplant Cytomegalovirus Infection: Study of Risk Factors
V. B. Kute et al.
TRANSPLANTATION PROCEEDINGS (2012)
First Report of Successful Treatment of Multidrug-Resistant Cytomegalovirus Disease with the Novel Anti-CMV Compound AIC246
D. R. Kaul et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials
D. C. Brennan et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Association of Cytomegalovirus Infection and Disease With Death and Graft Loss After Liver Transplant in High-Risk Recipients
W. Bosch et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysis
Andre C. Kalil et al.
CLINICAL INFECTIOUS DISEASES (2011)
QuantiFERON (R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity
Stefano Giulieri et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2011)
Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial
C. Ashley Finlen Copeland et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2011)
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
Paul D. Griffiths et al.
LANCET (2011)
Is Cytomegalovirus Infection Dangerous in Cytomegalovirus-Seropositive Recipients After Liver Transplantation?
Jong Man Kim et al.
LIVER TRANSPLANTATION (2011)
Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis
A. A. Boudreault et al.
TRANSPLANT INFECTIOUS DISEASE (2011)
The risk of cytomegalovirus recurrence after kidney transplantation
Ilkka Helantera et al.
TRANSPLANT INTERNATIONAL (2011)
The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response
Luiz F. Lisboa et al.
TRANSPLANTATION (2011)
Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant Recipients
Hans-Arne Myhre et al.
TRANSPLANTATION (2011)
Clinical Usefulness of Plasma Quantitative Polymerase Chain Reaction Assay: Diagnosis of Cytomegalovirus Infection in Kidney Transplant Recipients
J. -Y. Rhee et al.
TRANSPLANTATION PROCEEDINGS (2011)
Influence of Cytomegalovirus Disease in Outcome of Solid Organ Transplant Patients
L. Linares et al.
TRANSPLANTATION PROCEEDINGS (2011)
Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation
David R. Snydman et al.
TRANSPLANTATION PROCEEDINGS (2011)
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation
Scott M. Palmer et al.
ANNALS OF INTERNAL MEDICINE (2010)
Antiviral Drug Resistance of Human Cytomegalovirus
Nell S. Lurain et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Extended Valganciclovir Prophylaxis in D+/R- Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study
Atul Humar et al.
TRANSPLANTATION (2010)
International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation
Camille N. Kotton et al.
TRANSPLANTATION (2010)
Interlaboratory Comparison of Cytomegalovirus Viral Load Assays
X. L. Pang et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
A. Asberg et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
C Paya et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
分享论文
